298 related articles for article (PubMed ID: 29756394)
1. Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first-line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma.
Kang M; Yu J; Sung HH; Jeon HG; Jeong BC; Park SH; Jeon SS; Lee HM; Choi HY; Seo SI
Int J Urol; 2018 Jun; 25(6):596-603. PubMed ID: 29756394
[TBL] [Abstract][Full Text] [Related]
2. The De Ritis (aspartate transaminase/alanine transaminase) ratio as a predictor of oncological outcomes in patients after surgery for upper urinary tract urothelial carcinoma.
Cho YH; Hwang JE; Chung HS; Kim MS; Hwang EC; Jung SI; Kang TW; Kwon DD; Choi SH; Kim HT; Kim TH; Kwon TG; Noh JH; Kim MK; Kim CS; Kang SG; Kang SH; Cheon J; Lee CH; Ku JY; Ha HK; Tae BS; Jeong CW; Ku JH; Kwak C; Kim HH
Int Urol Nephrol; 2017 Aug; 49(8):1383-1390. PubMed ID: 28484945
[TBL] [Abstract][Full Text] [Related]
3. De Ritis ratio (aspartate transaminase/alanine transaminase ratio) as a significant prognostic factor after surgical treatment in patients with clear-cell localized renal cell carcinoma: a propensity score-matched study.
Lee H; Lee SE; Byun SS; Kim HH; Kwak C; Hong SK
BJU Int; 2017 Feb; 119(2):261-267. PubMed ID: 27226065
[TBL] [Abstract][Full Text] [Related]
4. Association between De Ritis ratio (aspartate aminotransferase/alanine aminotransferase) and oncological outcomes in bladder cancer patients after radical cystectomy.
Ha YS; Kim SW; Chun SY; Chung JW; Choi SH; Lee JN; Kim BS; Kim HT; Yoo ES; Kwon TG; Kim WT; Kim WJ; Kim TH
BMC Urol; 2019 Jan; 19(1):10. PubMed ID: 30678673
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of De Ritis ratio in metastatic renal cell carcinoma treated with tyrosine-kinase inhibitors.
Janisch F; Klotzbücher T; Marks P; Kienapfel C; Meyer CP; Yu H; Fühner C; Hillemacher T; Mori K; Mostafei H; Shariat SF; Fisch M; Dahlem R; Rink M
World J Urol; 2021 Aug; 39(8):2977-2985. PubMed ID: 33649869
[TBL] [Abstract][Full Text] [Related]
6. The significance of De Ritis (aspartate transaminase/alanine transaminase) ratio in predicting pathological outcomes and prognosis in localized prostate cancer patients.
Wang H; Fang K; Zhang J; Jiang Y; Wang G; Zhang H; Chen T; Shi X; Li Y; Duan F; Liu J
Int Urol Nephrol; 2017 Aug; 49(8):1391-1398. PubMed ID: 28550473
[TBL] [Abstract][Full Text] [Related]
7. Significance of De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Significant Prognostic But Not Predictive Biomarker in Japanese Patients with Metastatic Castration-resistant Prostate Cancer Treated with Cabazitaxel.
Miyake H; Matsushita Y; Watanabe H; Tamura K; Suzuki T; Motoyama D; Ito T; Sugiyama T; Otsuka A
Anticancer Res; 2018 Jul; 38(7):4179-4185. PubMed ID: 29970547
[TBL] [Abstract][Full Text] [Related]
8. Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma.
Laukhtina E; Pradere B; D Andrea D; Rosiello G; Luzzago S; Pecoraro A; Palumbo C; Knipper S; Karakiewicz PI; Margulis V; Quhal F; Sari Motlagh R; Mostafaei H; Mori K; Kimura S; Enikeev D; Shariat SF
Urol Oncol; 2020 Dec; 38(12):936.e7-936.e14. PubMed ID: 32962909
[TBL] [Abstract][Full Text] [Related]
9. Changeable Conditional Survival Rates and Associated Prognosticators in Patients with Metastatic Renal Cell Carcinoma Receiving First Line Targeted Therapy.
Kang M; Park JY; Jeong CW; Hwang EC; Song C; Hong SH; Kwak C; Chung J; Sung HH; Jeon HG; Jeong BC; Park SH; Jeon SS; Lee HM; Choi HY; Seo SI
J Urol; 2018 Nov; 200(5):989-995. PubMed ID: 29940249
[TBL] [Abstract][Full Text] [Related]
10. The effect of AST/ALT (De Ritis) ratio on survival and its relation to tumor histopathological variables in patients with localized renal cell carcinoma.
Canat L; Ataly HA; Agalarov S; Alkan I; Altunrende F
Int Braz J Urol; 2018; 44(2):288-295. PubMed ID: 29211398
[TBL] [Abstract][Full Text] [Related]
11. The De Ritis (Aspartate Transaminase/Alanine Transaminase) Ratio as a Prognosticator in Patients With End-stage Renal Disease-associated Renal Cell Carcinoma.
Ikeda T; Ishihara H; Takagi T; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Kondo T; Tanabe K
Clin Genitourin Cancer; 2020 Jun; 18(3):236-240.e1. PubMed ID: 31917171
[TBL] [Abstract][Full Text] [Related]
12. The Preoperative AST/ALT (De Ritis) Ratio Represents a Poor Prognostic Factor in a Cohort of Patients with Nonmetastatic Renal Cell Carcinoma.
Bezan A; Mrsic E; Krieger D; Stojakovic T; Pummer K; Zigeuner R; Hutterer GC; Pichler M
J Urol; 2015 Jul; 194(1):30-5. PubMed ID: 25623738
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment Serum Prealbumin as an Independent Prognostic Indicator in Patients With Metastatic Renal Cell Carcinoma Using Tyrosine Kinase Inhibitors as First-Line Target Therapy.
Cai W; Kong W; Dong B; Zhang J; Chen Y; Xue W; Huang Y; Zhou L; Huang J
Clin Genitourin Cancer; 2017 Jun; 15(3):e437-e446. PubMed ID: 28188047
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Preoperative Aspartate Transaminase/Alanine Transaminase Ratio as an Independent Predictive Biomarker in Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy: A Propensity Score Matching Study.
Ishihara H; Kondo T; Yoshida K; Omae K; Takagi T; Iizuka J; Tanabe K
Clin Genitourin Cancer; 2017 Oct; 15(5):598-604. PubMed ID: 28495053
[TBL] [Abstract][Full Text] [Related]
15. Aspartate transaminase/alanine transaminase (De Ritis ratio) predicts survival in major burn patients.
Wang B; Hu L; Chen Y; Zhu B; Kong W; Zhu Z; Wang K; Yu Q; Zhang W; Wu G; Sun Y; Xia Z
Burns; 2022 Jun; 48(4):872-879. PubMed ID: 34456097
[TBL] [Abstract][Full Text] [Related]
16. The prognostic significance of preoperatively assessed AST/ALT (De Ritis) ratio on survival in patients underwent radical cystectomy.
Gorgel SN; Kose O; Koc EM; Ates E; Akin Y; Yilmaz Y
Int Urol Nephrol; 2017 Sep; 49(9):1577-1583. PubMed ID: 28669104
[TBL] [Abstract][Full Text] [Related]
17. Prognostic role of preoperative De Ritis ratio in upper tract urothelial carcinoma treated with nephroureterectomy.
Mori K; Janisch F; Mostafaei H; Kimura S; Lysenko I; Karakiewicz PI; Briganti A; Enikeev DV; Rouprêt M; Margulis V; Chlosta P; Nyirady P; Babjuk M; Egawa S; Shariat SF
Urol Oncol; 2020 Jun; 38(6):601.e17-601.e24. PubMed ID: 32127252
[TBL] [Abstract][Full Text] [Related]
18. De Ritis Ratio (Aspartate Transaminase/Alanine Transaminase) as a Significant Prognostic Factor in Patients Undergoing Radical Cystectomy with Bladder Urothelial Carcinoma: A Propensity Score-Matched Study.
Yuk HD; Jeong CW; Kwak C; Kim HH; Ku JH
Dis Markers; 2019; 2019():6702964. PubMed ID: 31534562
[TBL] [Abstract][Full Text] [Related]
19. Editorial Comment from Dr Yuasa to Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with first-line systemic tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma.
Yuasa T
Int J Urol; 2018 Jun; 25(6):604-605. PubMed ID: 29764004
[No Abstract] [Full Text] [Related]
20. C-reactive protein is a predictor of prognosis in renal cell carcinoma patients receiving tyrosine kinase inhibitors: A meta-analysis.
Wang Z; Peng S; Wang A; Xie H; Guo L; Jiang N; Niu Y
Clin Chim Acta; 2017 Dec; 475():178-187. PubMed ID: 29080691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
